Cathleen June Park

4PUBLICATIONS
4CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|May 20, 2026
HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib - A Case Report.

|Jan 01, 2026
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report.

Alexandria T M Lee, Cathleen June Park, Zhaohui Liao Arter

|Oct 29, 2025
Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib.

Sai-Hong Ignatius Ou, Cathleen June Park, Zhaohui Liao Arter

|Jan 08, 2025
ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug Monitoring of ALK+ Non-Small Cell Lung Cancer?

Cathleen June Park, Alexandria T M Lee, Sai-Hong Ignatius Ou

Pageof 1

Frequent Collaborators

3 joint publications

Misako Nagasaka

3 joint publications

Zhaohui Liao Arter

3 joint publications

Sai-Hong Ignatius Ou

2 joint publications

Alexandria T M Lee